S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics
-
Narrated by:
-
By:
About this listen
Marc Shenouda, CEO and Co-Founder of Neuropeutics Inc., gives insights into targeted therapeutics for neurodegenerative disease, winning the AbbVie Biotech Innovator’s Award, and earlier detection for ALS.
Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.